Artelo Biosciences Secures $4.4 Million in Funding to Advance Clinical Trials for Cancer and Pain Therapeutics
核心洞察
Artelo Biosciences (搜索) raised $1.425 million through an at-the-market private placement and $3 million through a public offering to fund clinical development programs.
The company plans to use proceeds to announce clinical data from two Phase 1 studies for ART26.12 and Phase 2 CAReS trial results for ART27.13.
Artelo is developing proprietary therapeutics that modulate lipid-signaling pathways for cancer, pain, dermatological, and neurological conditions.
Artelo Biosciences (搜索), Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways, has secured approximately $4.4 million in combined funding through two separate offerings to advance its clinical development programs for cancer, pain, and other therapeutic areas.
Recent Financing Activities
The company completed a $1.425 million at-the-market private placement in June 2025, issuing 136,844 shares of common stock and 93,179 pre-funded warrants. The agreement also includes accompanying warrants to purchase 460,046 shares at $5.82 per share and 230,023 shares at $10.00 per share.
In a separate transaction, Artelo priced an underwritten public offering of 640,924 common shares at $4.40 each and pre-funded warrants for 40,894 shares at $4.399 each, generating gross proceeds of approximately $3 million before expenses and discounts. The public offering closed on September 5, 2025, with R.F. Lafferty & Co. (搜索), Inc. serving as the sole book-running manager.
Clinical Development Focus
The primary purpose of the private placement funding is to provide sufficient capital for Artelo to announce clinical data from its ongoing trials. Specifically, the company plans to release results from two Phase 1 studies for ART26.12 and Phase 2 study readout from the CAReS trial for ART27.13.
Artelo is advancing a portfolio of product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. The company's therapeutic approach centers on modulating lipid-signaling pathways, a mechanism that offers broad applicability across various medical conditions.
Capital Allocation Strategy
Under the terms of the private placement agreement, Artelo committed to use commercially reasonable efforts to allocate $250,000 of the net proceeds to purchase the digital currency SOL. The remaining proceeds from both offerings will support general corporate and working capital purposes, along with covering fees and expenses associated with the transactions.
Market Performance and Regulatory Status
Following the announcement of the public offering, Artelo's stock closed at $4.35 on Thursday, representing a 50.34% decline, but recovered 5.52% in after-hours trading to $4.59 on the NasdaqCM. The securities from the public offering were issued under Artelo's effective Form S-3 shelf registration statement, with underwriters holding a 45-day option to purchase up to 102,272 additional shares to cover over-allotments.
The company has agreed to file a registration statement covering the resale of securities issued in the private placement, as these securities were not registered under the Securities Act of 1933 and cannot be resold in the United States without proper registration or applicable exemptions.